-+ 0.00%
-+ 0.00%
-+ 0.00%

GH Research publishes corporate presentation on GH001 inhaled mebufotenin for treatment-resistant depression

PUBT·05/14/2026 11:13:53
Listen to the news
GH Research publishes corporate presentation on GH001 inhaled mebufotenin for treatment-resistant depression
  • GH Research outlined plans to initiate global Phase 3 trials in 2026 for GH001, an inhaled mebufotenin (5-MeO-DMT) candidate for treatment-resistant depression.
  • Phase 2b double-blind trial in TRD (n=81) reported least-squares mean placebo-adjusted MADRS change of -15.5 at Day 8 (P<0.0001), effect size Cohen’s d -2.0.
  • Open-label extension showed 73% remission at 6 months among protocol completers (n=63), with patients receiving mean of four treatments over 6 months.
  • Program highlighted short treatment burden, citing 99% of visits discharge-ready by 1 hour across more than 250 GH001 treatments, with median psychoactive experience of 11 minutes.
  • Balance sheet update showed cash, cash equivalents, and marketable securities of $267.3 million as of March 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.